Gujarat Inject Intrinsic Value
Gujarat Inject (GUJINJEC) median intrinsic value is ₹32.16 from 8 valuation models (range ₹21–₹54), vs current price ₹107.20 — -70.0% downside (Trading Above Calculated Value), margin of safety -100.0%. For current market price and key ratios, visit GUJINJEC stock price BSE.
GUJINJEC Valuation Methods Summary — DCF, Graham Number & P/E
Gujarat Inject intrinsic value across 8 models vs current price ₹107.20 — upside/downside and value range per method. Also explore Gujarat Inject stock price data download to track price trends across different timeframes.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹32.16 | ₹25.73 - ₹38.59 | -70.0% | EPS: ₹0.30, Sector P/E: 22x |
| Book Value Method | asset | ₹21.44 | ₹19.30 - ₹23.58 | -80.0% | Book Value/Share: ₹6.67, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹32.16 | ₹28.94 - ₹35.38 | -70.0% | Revenue/Share: ₹8.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹42.88 | ₹38.59 - ₹47.17 | -60.0% | EBITDA: ₹1.00Cr, EV/EBITDA: 10x |
| PEG Ratio Method | growth | ₹32.16 | ₹28.94 - ₹35.38 | -70.0% | EPS Growth: 20.0%, Fair P/E: 16.0x |
| Growth Adjusted P/E | growth | ₹32.16 | ₹28.94 - ₹35.38 | -70.0% | Revenue Growth: 15.0%, Adj P/E: 16.1x |
| ROE Based Valuation | profitability | ₹53.60 | ₹48.24 - ₹58.96 | -50.0% | ROE: 10.0%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹32.16 | ₹28.94 - ₹35.38 | -70.0% | EPS: ₹0.30, BVPS: ₹6.67 |
GUJINJEC Intrinsic Value vs Market Price — All Valuation Models
Gujarat Inject fair value range ₹21–₹54 vs current market price ₹107.20 across 8 valuation models. Browse GUJINJEC complete financial statements for revenue, profit, balance sheet and cash flow data.
GUJINJEC Intrinsic Value Analysis — Undervalued or Overvalued?
Gujarat Inject median intrinsic value ₹32.16, current price ₹107.20 — Trading Above Calculated Value by 70.0%, margin of safety -100.0%.
What is the intrinsic value of GUJINJEC?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Gujarat Inject (GUJINJEC) is ₹32.16 (median value). With the current market price of ₹107.20, this represents a -70.0% variance from our estimated fair value.
The valuation range spans from ₹21.44 to ₹53.60, indicating ₹21.44 - ₹53.60.
Is GUJINJEC undervalued or overvalued?
Based on our multi-method analysis, Gujarat Inject (GUJINJEC) appears to be trading above calculated value by approximately 70.0%.
GUJINJEC Financial Health — Key Ratios vs Industry Benchmarks
Gujarat Inject financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Debt to Equity Ratio | 1.20 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 10.0% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 4.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.00x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
GUJINJEC Cash Flow Quality — Operating & Free Cash Flow
Gujarat Inject operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2024 | ₹-6 Cr | ₹-6 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2020 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |